ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 94 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,136 | -83.0% | 4,357 | -69.5% | 0.01% | -78.3% |
| Q2 2023 | $136,155 | -96.1% | 14,287 | -95.5% | 0.02% | -96.6% |
| Q1 2023 | $3,488,672 | +15.6% | 317,152 | +55.6% | 0.67% | +14.9% |
| Q4 2022 | $3,017,010 | -28.6% | 203,852 | -7.8% | 0.58% | -29.8% |
| Q3 2022 | $4,223,000 | +10.1% | 220,985 | +22.8% | 0.83% | +7.6% |
| Q2 2022 | $3,836,000 | -9.1% | 180,016 | -17.9% | 0.77% | +3.2% |
| Q1 2022 | $4,221,000 | -16.5% | 219,136 | -10.1% | 0.75% | -1.6% |
| Q4 2021 | $5,055,000 | -72.1% | 243,736 | -67.9% | 0.76% | -49.5% |
| Q3 2021 | $18,127,000 | -12.5% | 758,763 | 0.0% | 1.51% | -10.0% |
| Q2 2021 | $20,707,000 | -18.6% | 758,763 | -13.7% | 1.68% | -13.1% |
| Q1 2021 | $25,428,000 | – | 878,948 | – | 1.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |